SCHEMBL23958331

SCHEMBL23958331

O=c1c2cccnc2nc(Nc2cccnc2)n1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL3 P58215 1/20 0.47
LOXL2 Q9Y4K0 1/20 0.47
ALOX12 P18054 1/20 0.46
RAD52 P43351 1/20 0.46
KMT2A Q03164 1/20 0.46
IDO1 P14902 2/20 0.44
PDE7A Q13946 1/20 0.43
RAB9A P51151 1/20 0.42
MDM2 Q00987 1/20 0.42
PDE5A O76074 2/20 0.41
MAPT P10636 2/20 0.41
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
CCND2 P30279 1/20 0.40
CCND3 P30281 1/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
FEN1 P39748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24110995 0.88 ALOX12 (0.57) ALOX12RAD52KMT2APDE7ARAB9A
SCHEMBL24110803 0.88 ALOX12 (0.40) LOXL3LOXL2ALOX12RAD52KMT2A
SCHEMBL23958216 0.87 ALOX12 (0.44) LOXL3LOXL2ALOX12RAD52KMT2A
SCHEMBL24110973 0.84 ALOX12 (0.47) LOXL3LOXL2ALOX12RAD52KMT2A
SCHEMBL24111000 0.83 ALOX12 (0.49) LOXL3LOXL2ALOX12RAD52KMT2A
SCHEMBL23958226 0.82 RAD52 (0.45) LOXL3LOXL2ALOX12RAD52KMT2A
SCHEMBL23958201 0.81 ALOX12 (0.43) LOXL3LOXL2ALOX12RAD52KMT2A
SCHEMBL23958356 0.81 ALOX12 (0.48) ALOX12RAD52KMT2APDE7ARAB9A
SCHEMBL23958349 0.81 PDE7A (0.47) LOXL3LOXL2ALOX12RAD52KMT2A
SCHEMBL23958215 0.79 MDM2 (0.49) ALOX12RAD52KMT2AMDM2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed
WO-2021215537-A1 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 (JP) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 LOXL3 578/4885LOXL2 1209/4885ALOX12 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.